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SUMMARY
A  pilot  study  was  performed  to  assess  the  effectiveness 
of treatment in an opioid dependent population using the 
Maudsley Addiction Profile (MAP) tool1.   
The primary outcome of the study was to assess if treatment 
had an effect on 1. Substance use (quantity and frequency 
of  use),  2.  Health  risk  behaviour  (injecting  and  sharing 
injecting  equipment),  3.  Health  symptoms  (physical 
and  psychological)  and  4.  Personal  /Social  functioning 
(relationships, employment and crime). A secondary outcome 
was also sought. 
The study took place in 2007 in an inner city Belfast hospital 
specialising in the treatment of addiction, over a two month 
period.  Fifteen patients, all opioid dependent and receiving 
outpatient community treatment, were interviewed at baseline 
(prior to the commencement of treatment) and at eight weeks 
follow up.  
Three patients were lost to follow up. Two patients stopped 
using altogether. Of the remaining patients, improvements 
were seen in most areas. There was a decrease in the use of 
heroin (71.28%), cocaine (99.72%), crack cocaine (100%), 
cannabis  (99.94%)  and  alcohol  (33.17%).  There  was  a 
reduction  in  injecting  behaviour  (60.93%).  Improvements 
were observed in health with a reduction in physical (41.35%) 
and psychological (35%) symptoms. Overall personal and 
social  functioning  improved  regarding  interactions  with 
family and friends. A reduction in crime was also observed 
(75%). 
Opinions  and  views  of  staff  involved  in  the  study  were 
generally positive.
This patient population presents with multiple and complex 
needs. Effective treatment needs to address these needs and 
not just drug addiction alone. The Maudsley Addiction Profile 
tool highlights this.
INTRODUCTION
The effect of drug misuse is felt by everyone2. It can affect 
the lives of individuals and communities. Drug misusers often 
have a set of complex problems. This needs to be taken into 
consideration if   recovery is going to be successful. Problems 
may range from unemployment, homelessness, involvement 
in criminal activities to poor physical (particularly the risk 
of  HIV ,  Hepatitis  B,  C  and  other  blood  borne  infections 
from sharing injecting equipment) and mental health issues. 
In Northern Ireland drug misuse has become a significant 
public health issue and costs hundreds of millions of pounds 
a year. In 2006 the government launched “A New Strategic 
Direction for Drugs 2006-2011”3. This document contained a 
number of concerns around the treatment of those who misuse 
drugs including prevention, treatment, harm reduction and 
monitoring.
METHODOLOGY
Substitute prescribing became policy in Northern Ireland in 
April 2004. Shaftesbury Square Hospital is located in the 
centre of Belfast and is involved in the treatment of all forms 
of drug and alcohol addictions - it covers a catchment area of 
370,000. The service provides substance misuse maintenance 
and  detoxification  programmes  and  offers  a  choice  of 
methadone or buprenorphine medication. It works in liaison 
with social services, housing and local psychiatric services. 
The patients can be referred by primary care, Drug Outreach 
Community Team (these are teams that work exclusively in 
the community), secondary care mental health services and 
the criminal justice system. A self referral system service is 
also in place. The substitution prescribing team consists of a 
part time administrative team member, four senior full-time 
nurses, a full time staff grade doctor, a half -time specialist 
registrar doctor with a consultant psychiatrist input.
In  this  study  all  patients  fulfilled  the  ICD10  criteria  of 
Substance  Dependence:  opioid  in  nature4.  The  ICD10 
categorises  the  mental  and  behavioural  disorders  due  to 
psychoactive substance use by drug types. Informed consent 
was  obtained. All  patients  were  fully  informed  about  the 
study. Confidentiality was assured and patients were given 
the option of withdrawing from the study if they decided to at 
any stage.  Patients were interviewed at baseline i.e. prior to 
commencement of treatment and at an eight week follow up. 
Patients were assessed on both occasions using the Maudsley 
Addiction Profile (MAP). The MAP is a brief questionnaire 
developed in the UK for assessing individuals with drug and 
alcohol problems. It is both reliable and valid5,6 and can be © The Ulster Medical Society, 2009.
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administered to patients in 15 minutes or less. The 30 day 
period before intake of treatment is used as the recall period 
for the MAP interview. It looks at four main areas: substance 
use, health risk behaviour, physical and psychological health 
and personal /social functioning.
All  patients  received  outpatient  community  treatment. 
This consisted of initial review by the medical team and 
weekly (or more frequent if needed) review by their team 
key worker (nursing and medical staff). Once stabilised this 
review could be decreased to fortnightly.  It is the practice of 
this service that the majority of patients commence opiate 
substitution treatment as an out patient (prescribed by primary 
care) whether it is for a detoxification or for a stabilization 
programme (unless it is decided by the team that for medical 
or  social  reasons  inpatient  treatment  is  required).  Urine 
screens  were  taken  at  regular  intervals  by  individual  key 
workers (i.e. nominated staff members) which would identify 
recent use of illicit substances. Boxes 1-4 show areas assessed.
A  secondary  outcome  using  a  qualitative  study  approach 
involving  staff  was  also  looked  at. All  staff  involved  in 
administering MAP was asked about their views of adding 
MAP to their initial assessment and at definite follow up 
periods.
Opinions  were  sought  to  explore  subjective  experience 
regarding  the  advantages  and  disadvantages  to  the 
introduction of MAP. 
RESULTS AT BASELINE 
All of the patients who had been accepted onto the opiate 
substitution programme at the start of January 2007 were 
included.  All  received  outpatient  community  treatment. 
15 people (13 male and 2 female) were interviewed. They 
ranged in ages between 30 and 55 years. Ten patients had self 
referred, two came from their GP (primary care), one came 
from the community addiction team (a team that works in a 
structured outpatient setting), one had been referred from a 
secondary mental service (i.e. from a psychiatrist) and one 
had come from the Drug Outreach Team, (a mobile outreach 
team that work exclusively in the community). None had been 
referred through the criminal justice system. 
All the patients were polydrug users i.e. using more then one 
type of drug at the time (Box 1). Ten patients reported using 
heroin. One patient had bought methadone. This was on top 
of his daily heroin use. Methadone is a controlled drug with 
a high dependency potential and a low lethal potential. Two 
patients admitted to buying Morphine sulphate tablets (MST). 
MST is an opioid analgesic and is used in severe pain. It does 
not have a licence to be used in opiate dependency.   
Four  patients  admitted  to  buying  Dihydrocodeine  (DHC) 
tablets. This was on top of one patient’s daily heroin use. 
Dihydrocodeine is an opioid analgesic and is used medically 
for moderate to severe pain. Repeated administration of DHC 
may cause dependency and tolerance. DHC does not have a 
licence for use in opiate substitution. One patient admitted 
to buying buprenorphine. This was not used on top of any 
other opioids. Buprenorphine is an opioid analgesic and its’ 
indications for use includes moderate to severe pain. It also 
has a licence for opiate substitution.  
Ten patients reported using alcohol for the thirty days prior 
to the study. This ranged from a pint of beer for one day (two 
units) to three pints of beer daily for seventeen days (102 
units). Seven of the patients had used cocaine in the thirty 
days previously. Cocaine is a stimulant drug. All admitted to 
snorting cocaine as opposed to injecting. 
Crack cocaine was used by four patients. One patient admitted 
to injecting crack cocaine whilst the other three took it orally. 
Six patients reported using Cannabis. 
Regarding health risk behaviour, five (four male and one 
female) admitted to injecting heroin (Box 2). None reported 
sharing injecting equipment. Of these five, three reported 
injecting on a daily basis up to twice a day. One reported 
injecting twenty five days of the thirty previous days again 
up to twice a day. The one female who admitted to injecting 
reported that she injecting twice a day for thirteen days. 
Five patients admitted to unprotected sexual contact. All five 
reported to be in a relationship with a partner at the time of 
the study (Box 2). All admitted to some form of physical 
symptoms (Box 3). The maximum score was 40. The highest 
score was 33 and the lowest score was 8. The most common 
symptoms were muscle pains/joint pains and tremors/shakes.
All  patients  admitted  to  some  form  of  psychological 
symptoms. The maximum score was 40. The highest score 
was 40. The lowest score was 8. The most common symptoms 
were “feeling tense” and “feeling no interest in things”.
In  personal/  social  functioning  eight  patients  were  in  a 
relationship with their partners at the time of this study (Box 
4). Six patients admitted to conflict. All patients had had 
some form of contact with their relatives. Four admitted to 
conflict with their relatives. Thirteen out of fourteen patients 
had  had  contact  with  friends  in  the  previous  thirty  days 
prior to engagement in treatment. Three patients admitted to 
conflict with friends. Only three patients admitted to working 
in the previous 30 days. One had worked six day, one was in 
full employment and one worked four days per week. Four 
patients admitted to being involved in some form of crime in 
the previous 30 days. Two had been involved in selling drugs 
on eight occasions. One admitted to one episode of shoplifting 
whilst another admitted to two episodes of shoplifting and 
nine episodes of being caught for possession of heroin. 
RESULTS AT EIGHT WEEKS FOLLOW UP
There were three patient lost to follow up. All three did not 
return  to  the  programme  after  the  initial  assessment.  Of 
these three drop outs two were male and one was female. All 
three were multiple drug users and were heavy users of illicit 
substances. Only one of the three had injected. Two patients 
had stopped using illicit drugs altogether.
For  substance  use  (Box  1)  five  patients  admitted  to  the 
continued use of heroin. Of these two admitted to continue 
injecting but denied sharing. The average total use per patient 
in the previous thirty days was 2.8g. This was a decrease of 
71.28%. There was no reported use of DHC (dihydrocodeine). 
One patient had taken an MST (morphine sulphate) tablet 
on  one  occasion. Three  patients  continued  to  drink. The 
average  total  units  consumed  per  patient  were  41.3  units 
which was a decrease of 33.17%. Two patients continued to © The Ulster Medical Society, 2009.
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use cocaine and the average total use per patient was 0.1g. 
This was a decrease of 99.72%. No patient reported the use 
of crack cocaine. Four patients continued to use cannabis. The 











Heroin (grams) 9.75 2.8
Alcohol (units) 61.8 41.3
Cocaine (grams) 35.9 0.1
Crack cocaine (grams) 21.8 0
Cannabis (grams) 18 1.01
For health risk behaviour (Box 2) two patients continued to 
inject. One patient injected twice one day. The other individual 
injected   twice a day for 19 days. The average total episodes 
per patient were 20 episodes. This was a decrease of 60.93%. 
Four patients continued to have unprotected sexual activity 
with their partners. The average total episodes per patient were 
7.75 which was a decrease of 0.6%.
BOX 2














With physical health (Box 3), all patients had reduced their 
scores. The average total score per patient was 11.6 which was 
reduction of 41.35%. All patients had reduced their scores in 
the psychological health domain. The average total score per 










Physical symptoms 19.78 11.6
Psychological symptoms 20.1 13
In the personal/ social functioning domain (Box 4), seven 
patients had contact with their partners and the average total 
days of contact per patient was 30 days which was an increase 
of 9%. Three patients continued to have conflict with their 
partners and the average total conflict days was 16.6 days 
which was an increase of 10.66%. 
11 patients continued to have contact with their relatives and 
the average total days of contact were 26.09 days which was 
an increase of 48.23%. Five patients continued to have conflict 
with their relatives and the average total days of conflict per 
patient were five days which was a decrease of 62.9%. 
12 patients continued to have contact with friends and the 
average total days of contact per patient were 20.5 days which 
was an increase of 14.28%. Two patients continued to have 
conflict with their friends and the average total days of conflict 
per patient in the previous thirty days were two days. This was 
a decrease of 81%.
Two  patients  continued  to  work  .One  worked  in  full 
employment and one worked for nine days. The average total 
days of employment per patient was 14.5 days which was an 
increase of 3%.
Only one patient had one episode of shop lifting which was 
a decrease of 75%.
BOX 4
Personal / Social 
Functioning
Baseline Av. 
total score per 
patient
Eight week follow 





















Employment  (days) 14 14.5
Crime (episodes) 7 1
QUALITATIVE RESULTS ON VIEWS OF MAP
Staff views regarding the administration of the Maudsley 
Addiction Profile: 
“The MAP was focused and direct and explored areas which 
may not necessarily be addressed. It provided material for 
work in further sessions”
“The MAP was easy to use and it did not impinge on other 
duties, it was completed during scheduled appointments”
“I could see the MAP been implemented into daily practice. 
However  there  were  concerns  raised  by  some  patients 
regarding  confidentiality  especially  those  with  a  criminal 
background”
“I found the questions very direct and patients found it easy 
to answer”
“The MAP provided information which often gets lost when 
focusing on screening results”
“It helps both the patient and staff member involved to see 
clearly if improvements have been made with treatment”
DISCUSSION
Interpretation of results 
Two patients had stopped using drugs altogether. Both of 
these were male. Both had injected and had been heavy users 
of drugs. Data was incomplete as three patients were lost © The Ulster Medical Society, 2009.
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to follow up at eight weeks due to the fact that they did not 
remain engaged with the addiction services. All three failed 
to return without reason. It was impossible to obtain any 
information regarding the status of these patients at the end 
of the study.  The concern here is that these dropouts may not 
be representative of those who completed the trial. 
The  majority  of  patients  in  this  study  were  male  which 
would  reflect  the  majority  of  addiction  studies.  Of  those 
that completed the study, most scores showed improvement 
during  treatment  although  it  is  not  clear  whether  the 
improvements were significant as no statistical tests were 
applied. All substance use i.e. in both frequency and quantity 
showed improvement. No patient was using crack cocaine at 
follow up. Multiple drug misuse is common in this patient 
population. Treatment outcomes can be extremely variable 
and varying degrees of improvement can exist. Evidence has 
shown that drug treatment is effective in reducing illegal drug 
misuse7-9. Better treatment outcomes have been found to be 
associated with time in treatment and whether treatment was 
completed10.  Retaining  patients  in  treatment  considerably 
enhances the benefits to both patients and society in general11. 
Early treatment drop-out is associated with a high risk of 
relapse to problem drug risk12.
In this study a reduction in the misuse of alcohol was seen. 
The World Health Organisation advises that the maximum 
recommended  levels  of  weekly  alcohol  consumption  are 
21 units for men and 14 units for females. Heavy drinking 
especially  alcohol  dependence  is  an  important  problem 
in drug misuse treatment and can sometimes be forgotten 
about. Dually (drug and alcohol) dependent individuals often 
have higher rates of criminal involvement and more health 
problems than drug misusers without drinking problems13. 
Heavy drinking causes a serious threat to the health of this 
group, especially as many have liver disease and impaired 
liver function14. The reduction regarding alcohol intake in 
this  study  could  be  due  to  a  number  of  factors.  Regular 
education around the use of alcohol and opiate substitution 
medication can improve awareness of the dangers of alcohol 
misuse. Another possible factor here could be that if any staff 
member has concerns of a patient’s use of alcohol whilst on 
the programme, suspension of opiate substitution medication 
can be sought.
Physical  and  psychological  scores  showed  improvement. 
In this study health risk behaviour showed improvement at 
follow up with decreased episodes of injecting behaviour. 
In 2005 The “Shooting Up” Report15 showed that there was 
an increase in the sharing of injecting equipment amongst 
injecting drug users. This recent research into drug injecting 
trends  amongst  those  using  heroin  and  crack/cocaine 
suggested a growing risk of blood borne virus transmission 
i.e. HIV , Hepatitis B and C infection. Shaftesbury Square 
Hospital as with other addiction services provides education     
around injecting risk and unprotected sexual risk behaviours. 
Studies show that reductions regarding instances of injecting 
and sharing injecting behaviour have been found 4-5 years 
after patients were admitted to treatment programmes16.
Psychological  symptoms  are  common  with  this  patient 
population especially those related to anxiety and depressive 
mood17.  Many  receive  treatment  for  a  psychiatric  health 
problem  other  than  substance  abuse.  Studies  have  shown 
that the severity of psychiatric disorder had been found to be 
related to poorer treatment outcomes18. In this study there was 
no information whether any of these patients were already 
engaged with mental health treatment i.e. primary care or 
secondary mental health services. 
Regarding personal/social functioning, all contact (partner, 
family and friends) improved. Interestingly though the average 
score of partner contact had improved, the average score of 
partner conflict showed an increase. Possible reasons for this 
could be that during the initial withdrawal period from drugs, 
patients will become more aware of their surroundings and 
their responsibilities. Giving up the drug life style can lead 
to thoughts of guilt and self- blame leading to interpersonal 
and intrapersonal conflict. 
There was a small increase in employment, however at follow 
up  two  patients  continued  to  work  compared  to  three  at 
baseline. There was a reduction observed in crime episodes 
with treatment and this reflects other studies findings19.
This study showed certain strengths. The subject researched 
was relevant to day-to-day practice in the Addiction Unit. All 
patients fulfilled the ICD10 criteria of Substance Dependence 
Syndrome. Sampled subjects were selected from the waiting 
list regardless of how they had been referred. There was no 
stringent inclusion or exclusion criteria. Data collection was 
systematic. 
The use of a qualitative approach was appropriate. The Opiate 
Prescribing team were asked about their personal opinions of 
incorporating the Maudsley Addiction Profile tool into their 
assessments. Staff were encouraged to be open and honest. 
Any relevant statements were written verbatim by the authors.
There were several limitations which need to be mentioned 
here. The study only consisted of 15 patients and had a short 
follow up period of eight weeks after the initial assessment. 
However  there  were  a  lot  of  similarities  in  the  results 
compared to previous studies20-22. Mean scores were taken 
and there was a lack of statistical analysis in this study. There 
was one patient who due to his high use of illicit use tended 
to skew the results. 
It is important to be aware that not all aspects related to a full 
research project can be thought of at this very early stage and 
may only become obvious when the larger research project 
is carried out e.g. problems about resources may arise later 
in a main study (although this pilot study did not require a 
significant investment of resources).  
In this study all of the patients received outpatient treatment. 
Due to the fact that only one form of treatment was used, 
no  comparison  can  be  performed  between  inpatient  and 
outpatient treatment. There was also no record if a patient was 
commencing an opiate detoxification or an opiate stabilisation 
programme.
The MAP tool is depending on self report of drug use and 
behaviour. There is the risk of the “Hawthorne effect”, in 
that the presence of the researcher may affect the behaviour 
of those researched. This is difficult to control for. Doubts 
are frequently expressed about the extent to which self-report 
screening  instruments  can  provide  an  accurate  picture  of 
substance use. Patients may not want to admit to their drug © The Ulster Medical Society, 2009.
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taking behaviour due to the fear of possibly not been accepted 
or retained in the treatment programme. In this study regular 
urine specimens were taken by the individual key worker 
to validate self report drug use. However it is important to 
remember that many of these illicit drugs have a very short 
wash-out period (i.e. they can leave the body quite quickly 
e.g.  heroin  2-4  days,  cocaine  12-72  hours).  These  illicit 
substances may therefore go undetected if patients are seen 
on a weekly basis.
It was difficult to quantify drug amounts. Many patients buy 
large quantities of drugs and make up their own drugs daily 
e.g. a joint of cannabis or a line of cocaine. The authors 
attempted  to  control  for  this  by  using  drug  standardised 
weights.
There were certain variables/factors omitted from the MAP 
assessment tool that should be considered and could influence 
outcome. Regarding the treatment of these patients in this 
study all were on some form of pharmacological treatment i.e. 
opiate substitution medication (methadone or buprenorphine), 
however doses were not recorded. Although all were seen 
weekly  by  their  key  worker  the  individual  sessions  were 
not  standardised.  Questions  regarding  accommodation 
arrangements (i.e. whether all patients at the time of the 
study were in stable accommodation or homeless) were not 
included. 
Despite the limitations of this study, the overall results were 
positive regarding when patients with a diagnosis of substance 
dependency engage with an opiate substitution prescribing 
service. The study addressed the effectiveness of treatment. 
The treatment of this population is difficult and complex. 
Recognition  of  these  factors  and  their  importance  helps 
treatment services more effectively.
From this pilot study a research question and plan can be 
developed.  Involved  service  providers  appeared  positive 
regarding their opinions and attitudes of the study. This may 
help to convince others that the main study is worth pursuing.
The authors have no conflict of interest.
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